Keyphrases
Outcome Prediction
100%
Prediction Method
100%
Malignant Pleural Mesothelioma
100%
Telomerase
100%
18F-FDG PET-CT
100%
Ipilimumab
100%
Nivolumab
100%
SUVpeak
100%
Metabolic Tumor Volume
80%
Multivariate Analysis
40%
SUVmax
40%
Standardized Uptake Value
40%
Total Lesion Glycolysis
40%
NIPU
40%
Non-associated
20%
Wilcoxon Rank Sum Test
20%
Treatment Response
20%
Cox Regression
20%
Univariate Analysis
20%
Progressive Disease
20%
Prognostic Value
20%
Objective Response
20%
Survival Outcomes
20%
Distinct Mechanism
20%
Complete Response
20%
Partial Response
20%
Solid Tumors
20%
Stable Disease
20%
Response Criteria
20%
Non-responders
20%
Early Reduction
20%
Response Evaluation Criteria in Solid Tumors (RECIST)
20%
Best Overall Response
20%
2-rank
20%
PET Metrics
20%
Medicine and Dentistry
Fluorodeoxyglucose F 18
100%
Positron Emission Tomography-Computed Tomography
100%
Pleura Mesothelioma
100%
Telomerase
100%
Prognosis
100%
Ipilimumab
100%
Nivolumab
100%
Neoplasm
80%
Immunotherapy
80%
Multivariate Analysis
40%
Standardized Uptake Value
40%
Rank Sum Test
20%
Disease
20%
Univariate Analysis
20%
Proportional Hazards Model
20%
Progressive Disease
20%
Treatment Response
20%
Positron Emission Tomography
20%
Solid Malignant Neoplasm
20%
Pharmacology, Toxicology and Pharmaceutical Science
Fluorodeoxyglucose F 18
100%
Pleura Mesothelioma
100%
Prognosis
100%
Ipilimumab
100%
Telomerase
100%
Nivolumab
100%
Neoplasm
80%
Immunotherapy
80%
Disease
40%
Solid Malignant Neoplasm
20%
Immunology and Microbiology
Vaccine Efficacy
100%
Immunotherapy
100%
Positron Emission Tomography-Computed Tomography
100%
Ipilimumab
100%
Metabolic Tumor Volume
100%
Nivolumab
100%